Thomas Cannell, Sesen
FDA rejects Sesen Bio's bladder cancer pitch, sending shares spiraling back to penny stock territory
Sesen Bio received some bad news Friday afternoon that it said was “unexpected,” briefly slashing shares by more than 80% and below $1 for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
